SCHEMBL26533899

SCHEMBL26533899

CC[C@H]1O[C@@H](c2scc3c(NC(=O)c4ccccc4)ncnc23)C[C@@H]1O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GALR3 O60755 1/20 0.36
▸ NR2F2 P24468 1/20 0.36
▸ CSF1R P07333 1/20 0.35
▸ BRD4 O60885 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ RPS6KB1 P23443 2/20 0.34
▸ EGFR P00533 1/20 0.34
▸ AURKB Q96GD4 1/20 0.34
▸ AURKA O14965 1/20 0.34
▸ ACACB O00763 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ P2RX3 P56373 1/20 0.33
▸ PDPK1 O15530 2/20 0.33
▸ NPC1 O15118 2/20 0.32
▸ RAB9A P51151 2/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ PDE4A P27815 1/20 0.32
▸ PDE4B Q07343 1/20 0.32
▸ PDE4C Q08493 1/20 0.32
▸ PDE4D Q08499 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26533894 0.92 GALR3 (0.44) GALR3NR2F2CSF1RBRD4NPSR1
SCHEMBL26534380 0.84 BRD4 (0.35) GALR3NR2F2CSF1RBRD4NPSR1
SCHEMBL26533906 0.77 ADORA1 (0.40) CSF1RHTTNPC1RAB9ASMN1; SMN2
SCHEMBL26534382 0.76 GALR3 (0.41) GALR3NR2F2CSF1RBRD4
SCHEMBL26533895 0.74 ACACB (0.33) BRD4NPSR1RPS6KB1EGFRAURKB
SCHEMBL12601699 0.73 ALDH1A1 (0.43) CSF1RNPC1RAB9ASMN1; SMN2
SCHEMBL13889496 0.73 ALDH1A1 (0.43) CSF1RNPC1RAB9ASMN1; SMN2
SCHEMBL18510821 0.73 TTK (0.36) GALR3NR2F2BRD4HTTNPC1
SCHEMBL26298205 0.73 ALDH1A1 (0.43) CSF1RNPC1RAB9ASMN1; SMN2
SCHEMBL25504687 0.72 ADORA3 (0.52) ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11787833-B2 Modified cyclic dinucleoside compounds as sting modulators ALIGOS THERAPEUTICS, INC. (US) 2023-10-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11787833-B2 Modified cyclic dinucleoside compounds as sting modulators STING1, CGAS, IRF3 GALR3 1461/4885NR2F2 661/4885CSF1R 1702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback